薄芝糖肽联合五痹胶囊佐治局限性硬皮病临床观察  

Clinical Observation of Bozhi Glycopeptide Combined with Wubi Capsules in the Adjuvant Treatment of Localized Scleroderma

作　　者：谷文佳 王春艳 熊建军 李晨 宋真真 李晓云 GU Wenjia;WANG Chunyan;XIONG Jianjun;LI Chen;SONG Zhenzhen;LI Xiaoyun(Shijiazhuang Ping'an Hospital,Shijiazhuang,Hebei,China 050000)

机构地区：[1]河北省石家庄平安医院,河北石家庄050000

出　　处：《中国药业》2025年第4期111-114,共4页China Pharmaceuticals

基　　金：河北省中医药管理局中医药类科研指令性计划课题[2021233]。

摘　　要：目的探讨薄芝糖肽联合五痹胶囊佐治局限性硬皮病的临床疗效及对患者可溶性白细胞介素2受体(sIL-2R)、胸腺和调控活化的趋化因子(TRAC)、成纤维细胞生长因子(FGF)水平的影响。方法选取医院2021年6月至2023年6月收治的局限性硬皮病患者60例,按随机数字表法分为观察组及对照组,各30例。两组患者均予光照治疗,观察组患者加予薄芝糖肽注射液静脉滴注及五痹胶囊口服。两组患者均以1个月为1个疗程,连续治疗3个疗程。结果观察组总有效率为96.67%,显著高于对照组的73.33%(P<0.05)。观察组患者治疗后的中医证候(包括皮硬肿胀、刺痛瘙痒、舌红脉弦)积分和皮肤硬度积分均显著低于对照组(P<0.05);sIL-2R、TRAC、FGF水平均显著低于对照组(P<0.05);补体C3、补体C4、CD40细胞水平均显著低于对照组,自然杀伤细胞水平均显著高于对照组(P<0.05)。观察组与对照组不良反应发生率相当(16.67%比13.33%,P>0.05)。结论薄芝糖肽联合五痹胶囊佐治局限性硬皮病,可减轻患者的中医证候,降低皮肤硬度评分,抑制sIL-2R、TRAC、FGF表达,提高免疫功能。Objective To investigate the clinical efficacy of Bozhi glycopeptide combined with Wubi Capsules in the adjuvant treatment of localized scleroderma,and its effect on the soluble interleukin-2 receptor(sIL-2R),thymus and activation-regulated chemokine(TRAC)and fibroblast growth factor(FGF)levels in patients.Methods Sixty patients with localized scleroderma admitted to the hospital from June 2021 to June 2023 were selected and randomly divided into the observation group and the control group by a random number table method,with 30 cases in each group.Both groups received phototherapy,on this basis,the patients in the observation group received intravenous drip of Bozhi Glycopeptide Injection and oral Wubi Capsules.All patients were treated for three courses with one month as a course.Results The total effective rate in the observation group was 96.67%,which was significantly higher than 73.33%in the control group(P<0.05).After treatment,the scores of traditional Chinese medicine(TCM)syndromes(including skin hardness,swelling,tingling,itching,tongue redness,pulse string)and skin hardness in the observation group were significantly lower than those in the control group(P<0.05);the sIL-2R,TRAC and FGF levels were significantly lower than those in the control group(P<0.05);the complement C3,complement C4 and CD40 cell levels were significantly lower than those in the control group,while the natural killer cell levels were significantly higher than those in the control group(P<0.05).The incidence of adverse reactions was comparable between the observation group and the control group(16.67%vs.13.33%,P>0.05).Conclusion The adjuvant treatment of Bozhi glycopeptide combined with Wubi Capsules can alleviate the TCM syndromes of patients with localized scleroderma,decrease the skin hardness score,inhibit the expression of sIL-2R,TRAC,FGF,and improve immune function.

关 键 词：局限性硬皮病 薄芝糖肽注射液 五痹胶囊 可溶性白细胞介素2受体 胸腺和调控活化的趋化因子 成纤维细胞生长因子 

分 类 号：R969.4[医药卫生—药理学]